What you should know about the US recall of NAFPIRA® (parathyroid hormone) for injection

November 29, 20XX

The National Institute of Health (NIH) has recently announced that NAFPIRA®, a medication used to treat certain bone diseases, will be voluntarily recalled due to a manufacturing defect. The recall affects all lots of NAFPIRA® manufactured by NAFPIRA Inc., a company based in California.

Why did the recall occur?

NAFPIRA, which is approved by the U.S. Food and Drug Administration (FDA), is a recombinant form of parathyroid hormone (PTH) used to treat osteoporosis in adults with vitamin D deficiency and hypoparathyroidism. The recall was initiated after the FDA discovered that a small number of vials contained an impurity that could cause serious health issues.

What are the potential risks?

Although the recall is voluntary, patients who have been prescribed NAFPIRA® should not continue to use the medication. The impurity, which is a byproduct of the manufacturing process, could cause a range of side effects, including bone pain, muscle weakness, and increased risk of fractures. In severe cases, it could lead to organ damage.

What should you do if you have NAFPIRA®?

If you have NAFPIRA® in your possession, you should immediately contact your healthcare provider. They will advise you on how to dispose of the medication safely and provide you with alternative treatment options.

What is the impact on patients and healthcare providers?

Healthcare providers are being advised to review their inventory and notify patients who may have been prescribed NAFPIRA®. Patients should not use the medication until they have consulted with their healthcare provider and have been advised that it is safe to do so.

In conclusion, the recall of NAFPIRA® is a serious matter that should be taken very seriously by patients and healthcare providers. It is important to follow the guidelines provided by the FDA and healthcare providers to ensure the safety and well-being of all involved.

Source: National Institute of Health